The European Commission has given its approval for the Spikevax XBB.1.5-adapted COVID-19 vaccine, developed by Moderna. This marks a significant milestone in the ongoing battle against the virus. It is the third adaptation of the Moderna vaccine designed to target new variants of COVID-19. The authorization comes as COVID-19 and seasonal influenza continue to circulate throughout the autumn and winter seasons. Vaccination is considered the most effective tool in combating both viruses.
Stella Kyriakides, the Commissioner for Health and Food Safety, emphasized the importance of vaccination, particularly for individuals aged 60 and above, those with weakened immune systems, and those with underlying health conditions. She urged these individuals to receive their booster dose using the latest adapted vaccines that target the current spreading variants. Kyriakides also highlighted the need for continued vigilance and mutual protection in the population.
The vaccine underwent a rigorous evaluation process by the European Medicines Agency (EMA) under the accelerated assessment mechanism. Following this evaluation, the European Commission granted authorization for the adapted vaccine through an expedited procedure. This would allow member states to adequately prepare for their autumn-winter vaccination campaigns.
The authorization of Moderna’s Spikevax XBB.1.5-adapted COVID-19 vaccine provides additional support to the ongoing vaccination efforts within the European Union. It reinforces the importance of staying updated with the latest vaccines to address emerging variants of the virus. The European Commission’s decision represents a commitment to protect public health and minimize the impact of COVID-19 and seasonal influenza.
Sources:
– European Commission
– European Medicines Agency
